Barinthus Biotherapeutics (NASDAQ:BRNS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB
Barinthus Biotherapeutics (NASDAQ:BRNS) had its price target raised by analysts at HC Wainwright from $3.00 to $4.00. They now have a "buy" rating on the stock.
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments